ABC/3TC/RPV (n = 66) (%) | ABC/3TC/EFV or boosted PIs (n = 104) (%) | p-value | |
---|---|---|---|
Age, years, median (IQR) | 35 (28–46) | 30 (30–49) | 0.04 |
Male | 63 (95.4) | 95 (91.3) | 0.37 |
Race | 0.40 | ||
Chinese | 45 (68.2) | 73 (70.2) | |
Malay | 16 (24.2) | 21 (20.2) | |
Indian | 5 (7.5) | 5 (4.8) | |
Others | 0 (0) | 5 (4.8) | |
HIV transmission route | 0.20 | ||
Homosexual | 42 (63.6) | 54 (52) | |
Heterosexual | 12 (18.2) | 30 (28.9) | |
Bisexual | 8 (12.1) | 18 (17.3) | |
IVDU + sexual contact | 2 (3.0) | 1 (1.1) | |
Others | 2 (3.0) | 1 (1) | |
Baseline viral load (copies/ml) | 0.42 | ||
< 10,000 | 21 (31.8) | 24 (23.1) | |
10,000–50,000 | 34 (51.5) | 58 (55.8) | |
> 50,000 | 11 (16.7) | 22 (21.2) | |
Baseline CD4 count | 0.37 | ||
200–350 | 21 (31.8) | 44 (42.3) | |
> 350–500 | 21 (31.8) | 30 (28.8) | |
> 500 | 24 (36.4) | 30 (28.8) | |
AIDS defining illness | 0 (0) | 0 (0) | NA |
HCV co-infection | 2 (3.0) | 3 (2.9) | 0.95 |
Genotype test at diagnosis | 29 (44.0) | 55 (52.9) | 0.26 |
Time from diagnosis to treatment, days, median (IQR) | 67 (45–215) | 84 (48–351) | 0.27 |
HLA B*5701 | <0.01 | ||
Positive | 0 (0) | 1 (1.0) | |
Negative | 61 (92.4) | 65 (62.5) | |
Not done | 5 (7.6) | 38 (36.5) | |
Comorbidities | |||
Diabetes mellitus | 5 (7.5) | 6 (5.8) | 0.64 |
Hypertension | 7 (10.6) | 9 (8.6) | 0.67 |
Hyperlipidemia | 5 (7.6) | 9 (8.7) | 0.80 |
IHD/CAD | 1 (1.5) | 2 (1.9) | 0.84 |
Congestive cardiac failure | 0 (0) | 0 (0) | NA |
Chronic liver disease | 0 (0) | 0 (0) | NA |
Chronic kidney disease | 0 (0) | 3 (2.9) | 0.16 |
Cancer | 0 (0) | 1 (1) | 0.42 |
CVA | 0 (0) | 0 (0) | NA |
Osteoporosis | 0 (0) | 0 (0) | NA |